DCA Treatment and Cancer
It is noted that cancer cells thrive in a low oxygen environment with low pH values and that raising the cell pH makes it hard for cancer cells to survive. DCA (Dichloroacetic Acid) is believed to work by turning on the oxygen-generating energy systems within all cells. It increases the oxygenation within the cancer cell and disrupts intracellular anaerobic metabolism. In an oxygenated environment, cancerous cells can no longer survive.
- Endometrial Cancer: DCA creates apoptosis in endometrial cancer cells.
- Endometrial Cancer: DCA causes apoptosis in endometrial cancer cells.
- Prostate Cancer: DCA produces significant cytotoxic effects in prostate cancer cells.
- Breast Cancer: DCA has anti-proliferative properties against breast cancer cells and caused apoptosis of those cells.
- Colorectal Cancer: DCA reduced colon cancer tumors by 20 to 40 percent.
- Cervical Cancer: Researchers concluded DCA is a quick and effective treatment for advanced cervical carcinoma.
DCA Treatment
At Sunridge Medical, our highly-trained physicians are experts in providing an integrated approach to the treatment of cancer and chronic disease. Our treatment plans are individualized and involve both traditional and alternative medicines including DCA. The physicians at Sunridge Medical have found that symptoms frequently can be improved and even reversed with our natural treatments. We take a holistic approach to patient care and strive not only to treat the disease, but also to alleviate symptoms, increase the quality of life and, most importantly, address the underlying cause of disease. References on DCA
An extensive body of literature describes anticancer properties of dichloroacetate (DCA), but its effective clinical administration in cancer therapy is still limited to clinical trials. The occurrence of side effects such as neurotoxicity as well as the suspicion of DCA carcinogenicity still restricts the clinical use of DCA. However, in the last years, the number of reports supporting DCA employment against cancer increased also because of the great interest in targeting metabolism of tumor cells.
Dissecting DCA mechanism of action helped to understand the bases of its selective efficacy against cancer cells. Successful coadministration of DCA with conventional chemotherapy, radiotherapy, other drugs, or natural compounds has been tested in several cancer models.
New drug delivery systems and multi-action compounds containing DCA and other drugs seem to ameliorate bioavailability and appear more efficient thanks to a synergistic action of multiple agents. The spread of reports supporting the efficiency of DCA in cancer therapy has prompted additional studies that led to find other potential molecular targets of DCA. Interestingly, DCA could significantly affect cancer stem cell fraction and contribute to cancer eradication. Collectively, these findings provide a strong rationale towards novel clinical translational studies of DCA in cancer therapy.
Chemodynamic therapy (CDT) based on Fenton or Fenton-like reactions is an emerging cancer treatment that can both effectively fight cancer and reduce side effects on normal cells and tissues, and it has made important progress in cancer treatment. The catalytic efficiency of Fenton nanocatalysts(F-NCs) directly determines the anticancer effect of CDT. To learn more about this new type of therapy, this review summarizes the recent development of F-NCs that are responsive to tumor microenvironment (TME), and introduces their material design and action mechanism.
Indeed, gene ontology analysis revealed altered expression of genes involved in the regulation of cellular proliferation, apoptosis, and the cell cycle in EGFR TKI-resistant cells. The present results demonstrate distinctive gene expression patterns of EGFR TKI-resistant lung cancer cells with the EGFR T790M mutation. The present study can provide key insights into gene expression profiles involved in conferring resistance to EGFR TKI therapy in lung cancer cells.
DCA and Cancer Stem Cell Eradication
An extensive body of literature describes the anticancer properties of dichloroacetate (DCA), but its effective clinical administration in cancer therapy is still limited to clinical trials. The occurrence of side effects such as neurotoxicity as well as the suspicion of DCA carcinogenicity still restricts the clinical use of DCA. However, in the last years, the number of reports supporting DCA employment against cancer increased also because of the great interest in targeting the metabolism of tumor cells. Dissecting the DCA mechanism of action helped to understand the bases of its selective efficacy against cancer cells.
Successful coadministration of DCA with conventional chemotherapy, radiotherapy, other drugs, or natural compounds has been tested in several cancer models. New drug delivery systems and multi-action compounds containing DCA and other drugs seem to ameliorate bioavailability and appear more efficient thanks to the synergistic action of multiple agents. The spread of reports supporting the efficiency of DCA in cancer therapy has prompted additional studies that led to finding other potential molecular targets of DCA. Interestingly, DCA could significantly affect cancer stem cell fraction and contribute to cancer eradication. Collectively, these findings provide a strong rationale for novel clinical translational studies of DCA in cancer therapy.
